Business Context and Reporting Period
This Form 8-K, filed on January 17, 2023, reports on events occurring on January 13, 2023, involving Calyxt, Inc. (the "Registrant") and Cibus Global LLC ("Cibus"). The filing details the entry into a definitive Merger Agreement to combine the two agricultural technology companies. The transaction is structured as a series of mergers resulting in an "Up-C" structure where the surviving public entity will hold membership units of Cibus. The closing is currently expected to occur in the second quarter of 2023.
Key Financial Metrics and Transaction Terms
The filing does not provide historical revenue, profit, or cash flow statements for either company. Key financial terms of the transaction include:
- Merger Consideration: Each Cibus membership unit converts into the right to receive 3.17046 shares of the Resulting Public Company's Class A Common Stock or Class B Common Stock (paired with Cibus Common Units).
- Ownership Structure: Upon closing, pre-Closing Calyxt stockholders are expected to own approximately 5.0% of the Resulting Public Company, while pre-Closing Cibus holders are expected to own approximately 95.0% (on a fully-diluted basis).
- Interim Funding: Cibus has agreed to provide Calyxt with an unsecured, interest-free revolving line of credit of up to $3,000,000 (potentially increasing to $4,000,000). This funding is available if Calyxt's unrestricted cash drops below $1,500,000 or starting March 15, 2023.
- Break Fees: A termination fee of $1,000,000 is payable by Calyxt to Cibus under specific termination scenarios (e.g., Board Recommendation Change, Superior Offer). Cibus may owe Calyxt $1,000,000 plus up to $500,000 in expenses if Cibus fails to deliver required consents or breaches the No-Shop provision.
Material Changes and Operational Focus
As a result of the merger discussions, Calyxt has narrowed its operational focus to ensure sufficient cash to achieve closing. The company is reducing operating expenses and concentrating on:
- Scaling production of its Plant Cell Matrix™ platform with manufacturing partner Evologic Technologies GmbH.
- Licensing efforts for PlantSpring™ technology and TALEN™ traits.
- Progressing three key customer projects: a soybean trait alternative to palm oil, a plant-based chemistry pilot, and late-stage development of an improved digestibility alfalfa trait.
Calyxt believes it has sufficient cash to fund operations through the end of the second quarter of 2023, supported by the Interim Funding agreement.
Guidance, Risks, and Contingencies
Conditions to Closing: The transaction is subject to Calyxt stockholder approval, Cibus member approval, regulatory approvals (including potential HSR Act filings), and the effectiveness of a Form S-4 registration statement.
Termination Rights: The agreement may be terminated if the Mergers are not consummated by May 15, 2023 (extendable to June 30, 2023), or if stockholder approval is not obtained. Calyxt may terminate to accept a Superior Offer, subject to paying the break fee.
Risks: Forward-looking statements are subject to risks including failure to satisfy closing conditions, uncertainties regarding timing, capital resource constraints, potential loss of key employees, and regulatory changes. The filing explicitly disclaims any obligation to update forward-looking statements.
Executive Compensation: Calyxt amended its 2021 Executive Severance Plan to change the payment schedule for severance benefits in the event of a change in control from a lump sum within 60 days to substantially equal installments over the coverage period.
Investor Verification Checklist
- Verify the final ownership percentages and conversion ratios in the upcoming Form S-4 proxy statement/prospectus.
- Confirm the status of the Interim Funding line of credit and Calyxt's current cash runway.
- Monitor the timeline for the Calyxt stockholder meeting and the effectiveness of the Form S-4.
- Review the "Risk Factors" in Calyxt's most recent 10-K and 10-Q filings for detailed operational and financial risks.
- Check for any updates regarding the "Superior Offer" provisions and the specific terms of the Tax Receivable Agreement.